Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
On January 14, 2021, the NIH updated its recommendation on the use of ivermectin in COVID-19. It removed its recommendation against the use of ivermectin in COVID-19. However it stated:
“There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19.”
The “Panel” consists of 47 medical experts and patient advocates. Presumably, recommendations in the Guidelines are endorsed by a vote of the Panel. However, there is ambiguity about voting since the Guidelines state:
“Updates to existing sections that do not affect the rated recommendations are approved by Panel co-chairs without a Panel vote.”
I submitted a Freedom of Information Act (FOIA) request to the NIH on January 25 to find out if there was a vote:
“On January 6, 2021, the NIH COVID-19 Treatment Guidelines Panel met to consider updating their recommendation on the use of Ivermectin in COVID-19. Please answer the following question. As of today, has that Panel taken a vote on w...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).